A significant progress has been made over the recent years in the treatment of metastatic ER-positive HER2-negative breast cancer: fulvestrant (500 mg) has been promoted to first line metastatic hormonal treatment (73) and CDK4/6 inhibitors have been established as a standard addition to endocrine agents (97). Here, ESR1 is linked to breast cancer.